57th ASH Annual Meeting and Exposition (December 5-8, 2015): 631. Chronic Myeloid Leukemia: Biology and Pathophysiology, excluding Therapy: Targeting Leukemic Stem Cells in Chronic Myeloid Leukemia

Chronic Myeloid Leukemia: Biology and Pathophysiology, excluding Therapy Oral and Poster Abstracts
Oral

W340, Level 3 (Orange County Convention Center)

Moderators:

Mhairi Copland, University of Glasgow and Ali G Turhan Sr., M.D., PhD, INSERM U935

Disclosures:

Copland: Novartis: Honoraria , Membership on an entity’s Board of Directors or advisory committees , Speakers Bureau ; Bristol-Myers Squibb: Honoraria , Membership on an entity’s Board of Directors or advisory committees , Research Funding ; Pfizer: Honoraria , Membership on an entity’s Board of Directors or advisory committees , Speakers Bureau ; Ariad: Honoraria , Membership on an entity’s Board of Directors or advisory committees , Speakers Bureau ; Gilead: Honoraria , Speakers Bureau .

9:30 AM

CD93 Is a Novel Biomarker of Leukemia Stem Cells in Chronic Myeloid Leukemia

Ross Kinstrie, PhD, BSc¹^*, Gillian A. Horne, BSc hons, MBChB, MRCP, MRES¹^*, Heather Morrison, BSc hons¹^*, Hothri A. Moka, BSc hons¹^*, Jennifer Cassels, BSc hons¹^*, Karen Dunn, BSc hons¹^*, Pawel Herzyk, MSc, PhD²^*, David A. Irvine, BSc, MBBChir, MRCP, FRCPath, PhD³ and Mhairi Copland, BSc (Hons) MB ChB PhD FRCP FRCPath¹

¹Paul O'Gorman Leukaemia Research Centre, University of Glasgow, Glasgow, United Kingdom
²Glasgow Polyomics, University of Glasgow, Glasgow, United Kingdom
³Bone Marrow Transplant Unit, Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom

9:45 AM

Targeting of Quiescent and Proliferating CML Stem Cells By DNA Repair Inhibitors

Katherine Sullivan¹^*, Elisabeth Bolton-Gillespie¹^*, Margaret Nieborowska-Skorska¹^*, Sabine Cerny-Reiterer, DVM²^*, Peter Valent, MD³, Markus Muschen, MD PhD⁴, Richard Pomerantz¹^*, Alexander Mazin⁵^* and Tomasz Skorski¹

¹Temple University School of Medicine, Philadelphia, PA
²Ludwig Boltzmann Cluster Oncology, Medical University of Vienna, Vienna, Austria
³Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria
⁴Department of Laboratory Medicine, University of California San Francisco, San Francisco, CA
⁵Drexel University, Philadelphia, PA

10:00 AM

Knockdown (KD) of Mir-126 Expression Enhances Tyrosine Kinase Inhibitor (TKI)-Mediated Targeting of Chronic Myelogenous Leukemia (CML) Stem Cells

Bin Zhang, PhD¹^*, Ling Li, PhD², Ching-Cheng Chen, PhD², Anthony S. Stein, MD³, Haris Ali, MD⁴^*, David S. Snyder, MD³, Allen Lin⁵^*, Adrienne Dorrance, PhD⁶^*, Piotr Swiderski, PhD⁷^*, Ravi Bhatia, MD⁸^*, Danilo Perrotti, MD, PhD⁹^*, Stephen J. Forman, MD¹⁰, Ya-Huei Kuo, PhD³, Marcin Kortylewski, PhD⁷^* and Guido Marcucci, MD²^*

¹Division of Hematopoietic Stem Cell & Leukemia, City of Hope National Medical Center, Duarte, CA
²Division of Hematopoietic Stem Cell and Leukemia Research of Beckman Research Institute, Gehr Family Center for Leukemia Research, City of Hope National Medical Center, Duarte, CA
³Gehr Family Center for Leukemia Research, City of Hope National Medical Center, Duarte, CA
⁴City of Hope, Duarte, CA
⁵Division of Hematopoietic Stem Cell and Leukemia Research of Beckman Research Institute, Gehr Family Center for Leukemia Research, City of Hope, Duarte, CA
⁶Ohio State University, Columbus, OH
⁷City of Hope National Medical Center, Duarte, CA
⁸University of Alabama Birmingham, Birmingham, AL
⁹University of Maryland, Baltimore, MD
¹⁰Hematology & Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA

10:15 AM

A New AHI-1-DNM2-BCR-ABL Complex Regulates Leukemic Properties of Primitive CML Cells through Mediation of Cellular Endocytosis and ROS-Induced Autophagy

Xiaohu Liu, MSc^1,2, Clark Fruhstorfer, BSc²^*, Katharina Rothe, BSc, MSc^2,3 and Xiaoyan Jiang, MD PhD^1,2,3

¹Department of Medicine, University of British Columbia, Vancouver, BC, Canada
²Terry Fox Laboratory, British Columbia Cancer Agency, Vancouver, BC, Canada
³Department of Medical Genetics, University of British Columbia, Vancouver, BC, Canada

10:30 AM

Role of the MSC-Derived Exosomal and Endogenous JAK2-SET/PP2A-Beta Catenin-Modulator Mir-300 in Leukemic Stem/Progenitor Proliferation and Survival in CML

Giovannino Silvestri, PhD¹^*, Lorenzo Stramucci, PhD¹^*, Justin Ellis²^*, Justine Yu³^*, Jason Harb, PhD⁴^*, Paolo Neviani, PhD⁵, Guido Marcucci, MD⁶^*, Klara Srutova⁷^*, Katerina Machova Polakova⁸^*, Denis-Claude Roy, MD⁹, Peter Hokland, M.D.¹⁰, Michael W. Deininger¹¹, Ravi Bhatia, MD¹²^*, Carlo Gambacorti-Passerini¹³, Dragana Milojkovic¹⁴^*, Alistair G Reid, BSc, PhD¹⁵^*, Jane F. Apperley, MD¹⁶, Ferenc Livak, PhD¹⁷^*, Maria R. Baer, MD¹⁸, Rossana Trotta, PhD¹⁹^* and Danilo Perrotti, MD, PhD²⁰

¹The Greenebaum Cancer Center, Dept. of Medicine, University of Maryland Baltimore, school of Medicine, Baltimore, MD
²The Ohio State University Comprehensive Cancer Center, Columbus, OH
³the Greenebaum Cancer Center, Dept. of Medicine, University of Maryland Baltimore, school of Medicine, Baltimore, MD
⁴Blood Research Institute BloodCenter of Wisconsin, Milwaukee, WI
⁵Norris Comprehensive Cancer Center, Children's Hospital Los Angeles, Los Angeles, CA
⁶Division of Hematopoietic Stem Cell and Leukemia Research of Beckman Research Institute, Gehr Family Center for Leukemia Research, City of Hope National Medical Center, Duarte, CA
⁷Institute of Hematology and Blood Transfusion, Prague, Czech Republic
⁸Institute of Hematology and Blood Transfusion, University of Prague, Prague, Czech Republic
⁹Department of Hematology and Cellular Therapy Laboratory, Hôpital Maisonneuve-Rosemont, University of Montreal, Montreal, QC, Canada
¹⁰Department of Hematology, Aarhus University Hospital, Aarhus, Denmark
¹¹Huntsman Cancer Institute, University of Utah, Salt Lake City, UT
¹²University of Alabama Birmingham, Birmingham, AL
¹³Azienda Ospedaliera San Gerardo/University of Milano-Bicocca, Monza, Italy
¹⁴Department of Haematology, Hammersmith Hospital (Imperial College Healthcare NHS Trust), London, United Kingdom
¹⁵Haematology Department, Hammersmith Hospital (Imperial College Healthcare NHS Trust), London, United Kingdom
¹⁶Department of Haematology, Imperial College London, Hammersmith Hospital, London, United Kingdom
¹⁷Microbiology and Immunology, University of Maryland Baltimore, school of Medicine, Baltimore, MD
¹⁸Greenebaum Cancer Center, University of Maryland Baltimore, Baltimore, MD
¹⁹Dept. microbiology and Immunology, University of Maryland Baltimore, school of Medicine, Baltimore, MD
²⁰Dept. Medicine, University of Maryland - Greenebaum Cancer Center, Baltimore, MD

10:45 AM

Inhibition of CML Stem Cell Renewal By the Porcupine Inhibitor WNT974

Puneet Agarwal, MS¹, Bin Zhang, PhD²^*, Yinwei Ho, MS²^*, Amy Cook, PhD²^*, Ling Li, PhD², Youzhen Wang, PhD³^*, Margaret E Mclaughlin, MD³^* and Ravi Bhatia, MD¹

¹Division of Hematology/Oncology, University of Alabama Birmingham, Birmingham, AL
²Division of Hematopoietic Stem Cell & Leukemia, City of Hope National Medical Center, Duarte, CA
³Translational Clinical Oncology, Novartis Institute of Biomedical Research, Cambridge, MA

See more of: Chronic Myeloid Leukemia: Biology and Pathophysiology, excluding Therapy
See more of: Oral and Poster Abstracts

<< Previous Session | Next Session >>

^*signifies non-member of ASH

631.O1.6 631. Chronic Myeloid Leukemia: Biology and Pathophysiology, excluding Therapy: Targeting Leukemic Stem Cells in Chronic Myeloid Leukemia